Full Title
A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Helena Yu’s office at 646-608-3912.
Protocol
26-049
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06706076